• Multiple Myeloma News
    • Feb 26, 2018

    Long-Term Follow-Up of MGUS Patients

An interesting article was published in the New England Journal of Medicine last month that reported on the long-term follow-up of MGUS patients. The article Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance summarizes the outcomes of 1,384 patients diagnosed with MGUS during the period 1960-1994. The median period that patients’ progress was followed and studied was 30.4 years. The primary endpoint of the study was the progression to myeloma or lymphoid disorder.

Some of the conclusions are:

  • ‘During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11%), a rate that was 6.5 times as high as the rate in the control population.’
  • On average, the risk of progression from MGUS to multiple myeloma increases at a rate of approximately 1 % per year after diagnosis. To be more specific the authors report ‘The risk of progression without accounting for death due to competing causes was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years.’
  • The authors also point out, however, that the risk of progression may be adversely impacted by the presence of two risk factors in patients with IgM MGUS ‘an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) — was associated with a risk of progression at 20 years of 55%, as compared with 41% among patients who had one adverse risk factor and 19% among patients who had neither risk factor.’
  • ‘Among patients with non-IgM MGUS, the risk of progression at 20 years was 30% among those who had the two risk factors, 20% among those who had one risk factor, and 7% among those who had neither risk factor.’

About Author

Paul Kleutghen

I've been a primary Plasma Cell Leukemia patient since January 2014. My wife, Vicki, and I have two adult kids and one grandson (the light of our lives). The PCL hasn’t stopped us from doing what we love the most : travel, albeit with some extra precautions these days. I've had a +20 year career in various aspects of the pharma industry and am a retired President/CEO of a generic pharmaceutical company. This photo is hanging on the “Survivor Wall” of the Duke Bone Marrow Transplant Center with the proverbial MM “ monkey on my back”.

$51,091 of $500,000 Raised
Please Help Us Reach Our Goal

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: